 | • レポートコード：MRC2-11QY04692 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は固形腫瘍薬のグローバル市場について調査・分析したレポートです。種類別（小分子、生物）市場規模、用途別（病院、診療所、学術研究機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別固形腫瘍薬の競争状況、市場シェア ・世界の固形腫瘍薬市場：種類別市場規模 2015年-2020年（小分子、生物） ・世界の固形腫瘍薬市場：種類別市場規模予測 2021年-2026年（小分子、生物） ・世界の固形腫瘍薬市場：用途別市場規模 2015年-2020年（病院、診療所、学術研究機関） ・世界の固形腫瘍薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、学術研究機関） ・北米の固形腫瘍薬市場分析：米国、カナダ ・ヨーロッパの固形腫瘍薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの固形腫瘍薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の固形腫瘍薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの固形腫瘍薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Hoffmann-La Roche、Novartis、Celgene、Johnson & Johnson、Pfizer、BMS、Eli Lilly、GSK、Merck、Sanofi、AbbVie、AstraZeneca、Bayer、Biogen、Boehringer Ingelheim、Boston Biomedical、Daiichi Sankyo ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.
During 2017, the biologics segment dominated the market and accounted for close to 55% of the market share in terms of revenue. This segment consists of medicinal products extracted from biological sources such as human, animal, microorganisms, or they are manufactured using the latest, cutting-edge biotechnological processes. Biologics include products such as enzymes, blood and blood components, gene therapy, recombinant proteins, somatic cells, tissues, and vaccines.
Market Analysis and Insights: Global Solid Tumors Drugs Market
The global Solid Tumors Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Solid Tumors Drugs Scope and Market Size
Solid Tumors Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Solid Tumors Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Hoffmann-La Roche
Novartis
Celgene
Johnson & Johnson
Pfizer
BMS
Eli Lilly
GSK
Merck
Sanofi
AbbVie
AstraZeneca
Bayer
Biogen
Boehringer Ingelheim
Boston Biomedical
Daiichi Sankyo
Market segment by Type, the product can be split into
Small Molecules
Biologics
Market segment by Application, split into
Hospitals
Clinics
Academic and Research Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Solid Tumors Drugs Revenue
1.4 Market by Type
1.4.1 Global Solid Tumors Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Small Molecules
1.4.3 Biologics
1.5 Market by Application
1.5.1 Global Solid Tumors Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Academic and Research Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Solid Tumors Drugs Market Perspective (2015-2026)
2.2 Global Solid Tumors Drugs Growth Trends by Regions
2.2.1 Solid Tumors Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Solid Tumors Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Solid Tumors Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Solid Tumors Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Solid Tumors Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Solid Tumors Drugs Players by Market Size
3.1.1 Global Top Solid Tumors Drugs Players by Revenue (2015-2020)
3.1.2 Global Solid Tumors Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Solid Tumors Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Solid Tumors Drugs Market Concentration Ratio
3.2.1 Global Solid Tumors Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Solid Tumors Drugs Revenue in 2019
3.3 Solid Tumors Drugs Key Players Head office and Area Served
3.4 Key Players Solid Tumors Drugs Product Solution and Service
3.5 Date of Enter into Solid Tumors Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Solid Tumors Drugs Historic Market Size by Type (2015-2020)
4.2 Global Solid Tumors Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Solid Tumors Drugs Market Size by Application (2015-2020)
5.2 Global Solid Tumors Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Solid Tumors Drugs Market Size (2015-2020)
6.2 Solid Tumors Drugs Key Players in North America (2019-2020)
6.3 North America Solid Tumors Drugs Market Size by Type (2015-2020)
6.4 North America Solid Tumors Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Solid Tumors Drugs Market Size (2015-2020)
7.2 Solid Tumors Drugs Key Players in Europe (2019-2020)
7.3 Europe Solid Tumors Drugs Market Size by Type (2015-2020)
7.4 Europe Solid Tumors Drugs Market Size by Application (2015-2020)
8 China
8.1 China Solid Tumors Drugs Market Size (2015-2020)
8.2 Solid Tumors Drugs Key Players in China (2019-2020)
8.3 China Solid Tumors Drugs Market Size by Type (2015-2020)
8.4 China Solid Tumors Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Solid Tumors Drugs Market Size (2015-2020)
9.2 Solid Tumors Drugs Key Players in Japan (2019-2020)
9.3 Japan Solid Tumors Drugs Market Size by Type (2015-2020)
9.4 Japan Solid Tumors Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Solid Tumors Drugs Market Size (2015-2020)
10.2 Solid Tumors Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Solid Tumors Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Solid Tumors Drugs Market Size by Application (2015-2020)
11 India
11.1 India Solid Tumors Drugs Market Size (2015-2020)
11.2 Solid Tumors Drugs Key Players in India (2019-2020)
11.3 India Solid Tumors Drugs Market Size by Type (2015-2020)
11.4 India Solid Tumors Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Solid Tumors Drugs Market Size (2015-2020)
12.2 Solid Tumors Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Solid Tumors Drugs Market Size by Type (2015-2020)
12.4 Central & South America Solid Tumors Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Hoffmann-La Roche
13.1.1 Hoffmann-La Roche Company Details
13.1.2 Hoffmann-La Roche Business Overview
13.1.3 Hoffmann-La Roche Solid Tumors Drugs Introduction
13.1.4 Hoffmann-La Roche Revenue in Solid Tumors Drugs Business (2015-2020))
13.1.5 Hoffmann-La Roche Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Solid Tumors Drugs Introduction
13.2.4 Novartis Revenue in Solid Tumors Drugs Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Celgene
13.3.1 Celgene Company Details
13.3.2 Celgene Business Overview
13.3.3 Celgene Solid Tumors Drugs Introduction
13.3.4 Celgene Revenue in Solid Tumors Drugs Business (2015-2020)
13.3.5 Celgene Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Solid Tumors Drugs Introduction
13.4.4 Johnson & Johnson Revenue in Solid Tumors Drugs Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
13.5 Pfizer
13.5.1 Pfizer Company Details
13.5.2 Pfizer Business Overview
13.5.3 Pfizer Solid Tumors Drugs Introduction
13.5.4 Pfizer Revenue in Solid Tumors Drugs Business (2015-2020)
13.5.5 Pfizer Recent Development
13.6 BMS
13.6.1 BMS Company Details
13.6.2 BMS Business Overview
13.6.3 BMS Solid Tumors Drugs Introduction
13.6.4 BMS Revenue in Solid Tumors Drugs Business (2015-2020)
13.6.5 BMS Recent Development
13.7 Eli Lilly
13.7.1 Eli Lilly Company Details
13.7.2 Eli Lilly Business Overview
13.7.3 Eli Lilly Solid Tumors Drugs Introduction
13.7.4 Eli Lilly Revenue in Solid Tumors Drugs Business (2015-2020)
13.7.5 Eli Lilly Recent Development
13.8 GSK
13.8.1 GSK Company Details
13.8.2 GSK Business Overview
13.8.3 GSK Solid Tumors Drugs Introduction
13.8.4 GSK Revenue in Solid Tumors Drugs Business (2015-2020)
13.8.5 GSK Recent Development
13.9 Merck
13.9.1 Merck Company Details
13.9.2 Merck Business Overview
13.9.3 Merck Solid Tumors Drugs Introduction
13.9.4 Merck Revenue in Solid Tumors Drugs Business (2015-2020)
13.9.5 Merck Recent Development
13.10 Sanofi
13.10.1 Sanofi Company Details
13.10.2 Sanofi Business Overview
13.10.3 Sanofi Solid Tumors Drugs Introduction
13.10.4 Sanofi Revenue in Solid Tumors Drugs Business (2015-2020)
13.10.5 Sanofi Recent Development
13.11 AbbVie
10.11.1 AbbVie Company Details
10.11.2 AbbVie Business Overview
10.11.3 AbbVie Solid Tumors Drugs Introduction
10.11.4 AbbVie Revenue in Solid Tumors Drugs Business (2015-2020)
10.11.5 AbbVie Recent Development
13.12 AstraZeneca
10.12.1 AstraZeneca Company Details
10.12.2 AstraZeneca Business Overview
10.12.3 AstraZeneca Solid Tumors Drugs Introduction
10.12.4 AstraZeneca Revenue in Solid Tumors Drugs Business (2015-2020)
10.12.5 AstraZeneca Recent Development
13.13 Bayer
10.13.1 Bayer Company Details
10.13.2 Bayer Business Overview
10.13.3 Bayer Solid Tumors Drugs Introduction
10.13.4 Bayer Revenue in Solid Tumors Drugs Business (2015-2020)
10.13.5 Bayer Recent Development
13.14 Biogen
10.14.1 Biogen Company Details
10.14.2 Biogen Business Overview
10.14.3 Biogen Solid Tumors Drugs Introduction
10.14.4 Biogen Revenue in Solid Tumors Drugs Business (2015-2020)
10.14.5 Biogen Recent Development
13.15 Boehringer Ingelheim
10.15.1 Boehringer Ingelheim Company Details
10.15.2 Boehringer Ingelheim Business Overview
10.15.3 Boehringer Ingelheim Solid Tumors Drugs Introduction
10.15.4 Boehringer Ingelheim Revenue in Solid Tumors Drugs Business (2015-2020)
10.15.5 Boehringer Ingelheim Recent Development
13.16 Boston Biomedical
10.16.1 Boston Biomedical Company Details
10.16.2 Boston Biomedical Business Overview
10.16.3 Boston Biomedical Solid Tumors Drugs Introduction
10.16.4 Boston Biomedical Revenue in Solid Tumors Drugs Business (2015-2020)
10.16.5 Boston Biomedical Recent Development
13.17 Daiichi Sankyo
10.17.1 Daiichi Sankyo Company Details
10.17.2 Daiichi Sankyo Business Overview
10.17.3 Daiichi Sankyo Solid Tumors Drugs Introduction
10.17.4 Daiichi Sankyo Revenue in Solid Tumors Drugs Business (2015-2020)
10.17.5 Daiichi Sankyo Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Solid Tumors Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Solid Tumors Drugs Revenue
Table 3. Ranking of Global Top Solid Tumors Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Solid Tumors Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Small Molecules
Table 6. Key Players of Biologics
Table 7. Global Solid Tumors Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Solid Tumors Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Solid Tumors Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Solid Tumors Drugs Market Share by Regions (2015-2020)
Table 11. Global Solid Tumors Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Solid Tumors Drugs Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Solid Tumors Drugs Market Growth Strategy
Table 17. Main Points Interviewed from Key Solid Tumors Drugs Players
Table 18. Global Solid Tumors Drugs Revenue by Players (2015-2020) (Million US$)
Table 19. Global Solid Tumors Drugs Market Share by Players (2015-2020)
Table 20. Global Top Solid Tumors Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Solid Tumors Drugs as of 2019)
Table 21. Global Solid Tumors Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Solid Tumors Drugs Product Solution and Service
Table 24. Date of Enter into Solid Tumors Drugs Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 27. Global Solid Tumors Drugs Market Size Share by Type (2015-2020)
Table 28. Global Solid Tumors Drugs Revenue Market Share by Type (2021-2026)
Table 29. Global Solid Tumors Drugs Market Size Share by Application (2015-2020)
Table 30. Global Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 31. Global Solid Tumors Drugs Market Size Share by Application (2021-2026)
Table 32. North America Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 34. North America Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 35. North America Solid Tumors Drugs Market Share by Type (2015-2020)
Table 36. North America Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 37. North America Solid Tumors Drugs Market Share by Application (2015-2020)
Table 38. Europe Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 40. Europe Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Solid Tumors Drugs Market Share by Type (2015-2020)
Table 42. Europe Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Solid Tumors Drugs Market Share by Application (2015-2020)
Table 44. China Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 45. China Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 46. China Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 47. China Solid Tumors Drugs Market Share by Type (2015-2020)
Table 48. China Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 49. China Solid Tumors Drugs Market Share by Application (2015-2020)
Table 50. Japan Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 52. Japan Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Solid Tumors Drugs Market Share by Type (2015-2020)
Table 54. Japan Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Solid Tumors Drugs Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 58. Southeast Asia Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Solid Tumors Drugs Market Share by Type (2015-2020)
Table 60. Southeast Asia Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Solid Tumors Drugs Market Share by Application (2015-2020)
Table 62. India Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 63. India Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 64. India Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 65. India Solid Tumors Drugs Market Share by Type (2015-2020)
Table 66. India Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 67. India Solid Tumors Drugs Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Solid Tumors Drugs Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Solid Tumors Drugs Market Share (2019-2020)
Table 70. Central & South America Solid Tumors Drugs Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Solid Tumors Drugs Market Share by Type (2015-2020)
Table 72. Central & South America Solid Tumors Drugs Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Solid Tumors Drugs Market Share by Application (2015-2020)
Table 74. Hoffmann-La Roche Company Details
Table 75. Hoffmann-La Roche Business Overview
Table 76. Hoffmann-La Roche Product
Table 77. Hoffmann-La Roche Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 78. Hoffmann-La Roche Recent Development
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Product
Table 82. Novartis Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 83. Novartis Recent Development
Table 84. Celgene Company Details
Table 85. Celgene Business Overview
Table 86. Celgene Product
Table 87. Celgene Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 88. Celgene Recent Development
Table 89. Johnson & Johnson Company Details
Table 90. Johnson & Johnson Business Overview
Table 91. Johnson & Johnson Product
Table 92. Johnson & Johnson Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 93. Johnson & Johnson Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Product
Table 97. Pfizer Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 98. Pfizer Recent Development
Table 99. BMS Company Details
Table 100. BMS Business Overview
Table 101. BMS Product
Table 102. BMS Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 103. BMS Recent Development
Table 104. Eli Lilly Company Details
Table 105. Eli Lilly Business Overview
Table 106. Eli Lilly Product
Table 107. Eli Lilly Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 108. Eli Lilly Recent Development
Table 109. GSK Business Overview
Table 110. GSK Product
Table 111. GSK Company Details
Table 112. GSK Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 113. GSK Recent Development
Table 114. Merck Company Details
Table 115. Merck Business Overview
Table 116. Merck Product
Table 117. Merck Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 118. Merck Recent Development
Table 119. Sanofi Company Details
Table 120. Sanofi Business Overview
Table 121. Sanofi Product
Table 122. Sanofi Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 123. Sanofi Recent Development
Table 124. AbbVie Company Details
Table 125. AbbVie Business Overview
Table 126. AbbVie Product
Table 127. AbbVie Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 128. AbbVie Recent Development
Table 129. AstraZeneca Company Details
Table 130. AstraZeneca Business Overview
Table 131. AstraZeneca Product
Table 132. AstraZeneca Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 133. AstraZeneca Recent Development
Table 134. Bayer Company Details
Table 135. Bayer Business Overview
Table 136. Bayer Product
Table 137. Bayer Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 138. Bayer Recent Development
Table 139. Biogen Company Details
Table 140. Biogen Business Overview
Table 141. Biogen Product
Table 142. Biogen Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 143. Biogen Recent Development
Table 144. Boehringer Ingelheim Company Details
Table 145. Boehringer Ingelheim Business Overview
Table 146. Boehringer Ingelheim Product
Table 147. Boehringer Ingelheim Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 148. Boehringer Ingelheim Recent Development
Table 149. Boston Biomedical Company Details
Table 150. Boston Biomedical Business Overview
Table 151. Boston Biomedical Product
Table 152. Boston Biomedical Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 153. Boston Biomedical Recent Development
Table 154. Daiichi Sankyo Company Details
Table 155. Daiichi Sankyo Business Overview
Table 156. Daiichi Sankyo Product
Table 157. Daiichi Sankyo Revenue in Solid Tumors Drugs Business (2015-2020) (Million US$)
Table 158. Daiichi Sankyo Recent Development
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Solid Tumors Drugs Market Share by Type: 2020 VS 2026
Figure 2. Small Molecules Features
Figure 3. Biologics Features
Figure 4. Global Solid Tumors Drugs Market Share by Application: 2020 VS 2026
Figure 5. Hospitals Case Studies
Figure 6. Clinics Case Studies
Figure 7. Academic and Research Institutes Case Studies
Figure 8. Solid Tumors Drugs Report Years Considered
Figure 9. Global Solid Tumors Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 10. Global Solid Tumors Drugs Market Share by Regions: 2020 VS 2026
Figure 11. Global Solid Tumors Drugs Market Share by Regions (2021-2026)
Figure 12. Porter's Five Forces Analysis
Figure 13. Global Solid Tumors Drugs Market Share by Players in 2019
Figure 14. Global Top Solid Tumors Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Solid Tumors Drugs as of 2019
Figure 15. The Top 10 and 5 Players Market Share by Solid Tumors Drugs Revenue in 2019
Figure 16. North America Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 17. Europe Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. China Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Japan Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Southeast Asia Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. India Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Central & South America Solid Tumors Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Bottom-up and Top-down Approaches for This Report
Figure 24. Data Triangulation
Figure 25. Key Executives Interviewed
消化管間質腫瘍（GIST）治療の世界市場（～2026年） A Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the gastrointestinal tract and most commonly in the stomach or small intestine. Market Analysis and Insights: Global Gastrointestinal Stromal Tumors (GISTs) Treatment Market The global Gastrointestinal Stromal Tumors (GISTs) …- OTC外用薬の世界市場（～2026年） Topical drugs are used for the application where body surfaces such as the skin or mucous membranes to treat ailments. OTC Topical drugs are epicutaneous medication that are applied in the skin directly. The large range of classes included in the topical drugs are creams, foams, gels, lotions and oi…
- 膀胱がん治療薬の世界市場（～2026年） Bladder cancer refers to the growth of abnormal tissues in the lining of the bladder. These abnormal tissues are referred to as tumor, which even spread in the surrounding tissues or muscles. The increase in prevalence of bladder cancer, advanced health care services, technological advancements, dr…
- 網膜薬及び生物製剤の世界市場（～2026年） A biologic is manufactured in a living system such as a microorganism, or plant or animal cells. Most biologics are very large, complex molecules or mixtures of molecules. Many biologics are produced using recombinant DNA technology. Global Retinal Drugs and Biologics market is highly fragmented wit…
- テネクテプラーゼ薬の世界市場（～2026年） Tenecteplase drug is an enzyme derived through recombinant DNA technology from a human cell line. This enzyme is used to treat thrombus (blood clots) it is also called as clot-busting drug. Tenecteplase is a bioengineered variant of the activase drug. It is estimated that North America dominated the…